Trillium Therapeutics Inchares (NASDAQ:TRIL) Shorts Declined By 7.66% As Of Jun 27, 2018

June 27, 2018 - By Ira Colvard

Trillium Therapeutics Inchares (NASDAQ:TRIL) had a decrease of its shorted shares by 7.66%. FINRA issued in June TRIL’s total 176,100 shorted shares. The down change of 7.66% from 190,700 shares was reported. 2 days will cost TRIL with 75,600 average volume to recover its previous position. Float short on Trillium Therapeutics Inchares is 2.42%.

The stock increased 2.46% or $0.15 during the last trading session, hitting $6.25.Currently Trillium Therapeutics Inc. is uptrending after 11.93% change in last June 27, 2017. TRIL has 63,173 shares volume. The stock underperformed the S&P500 by 0.64%.

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer.The firm is worth $85.68 million. The companyÂ’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.Last it reported negative earnings. The Company’s product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase.

Trillium Therapeutics Inc. (NASDAQ:TRIL) Ratings Coverage

In total 2 analysts cover Trillium Therapeutics (NASDAQ:TRIL). “Buy” rating has 1, “Sell” are 0, while 1 are “Hold”. 50% are bullish. With $10.0 highest and $700 lowest target price Trillium Therapeutics has $8.50 average target price or 36.00% above the current ($6.25) price. 3 are the (NASDAQ:TRIL)’s analyst reports since March 12, 2018 according to StockzIntelligence Inc. On Friday, April 13 the company was initiated by Leerink Swann. On Monday, May 14 the firm earned “Buy” rating by H.C. Wainwright. The company rating was maintained by H.C. Wainwright on Monday, March 12.

For more Trillium Therapeutics Inc. (NASDAQ:TRIL) news published briefly go to: Benzinga.com, Nasdaq.com, Nasdaq.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “44 Biggest Movers From Yesterday” published on June 12, 2018, “Trillium Therapeutics Appoints Yaping Shou, MD, PhD as Chief Medical Officer” on June 07, 2018, “Trillium Therapeutics Announces “At-The-Market” Issuance Program and Filing of Prospectus Supplement” with a publish date: June 19, 2018, “Trillium up 13% premarket” and the last “Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders” with publication date: June 05, 2018.

Trillium Therapeutics Inc. (NASDAQ:TRIL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.